Credence MedSystems gets $15M infusion of Series A financing

Credence MedSystems, a medical technology company based in Menlo Park, CA, got a $15 million injection in a Series A round of financing.

Details of the funding weren’t disclosed, but the company said it will use the money to continue development of its drug delivery platform that is based on prefilled devices and sold to drug manufacturers to use with their injectable medications.

Credence’s products include the Companion platform of passive needle safety prefillable syringes, which have staked needle, luer needle, and dual chamber reconstitution options.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Patients use the device to perform an injection, after which it gives a cue that the drug has been delivered and the needle automatically retracts into the syringe, which is then disabled from being used again.

“This financing comes at a time when our Company is rapidly gaining customer traction and provides our team with additional resources to continue the development of our highly innovative drug delivery platforms,” Jeff Tillack, Credence’s COO, said in a statement. “We are providing solutions that meet the unmet needs of the pharmaceutical industry for safe, cost effective and easy to implement next generation products.”

The company also said it’s developing additional products aimed at delivery of biologics to patients.

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.